Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,540.00-0.27%ETH$2,396.99-0.23%GOLD$4,036.10-0.60%OIL$101.47+2.01%
Smart Investors Daily
SID Premium
HC

NASDAQ · HCWB

HCW Biologics Inc.

Healthcare · Biotechnology

$1.12

Down-$0.04 (-3.45%)

Updated Oct 23, 2026, 12:06 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.25M
P/E ratio
-0.2
Dividend yield
0.00%
52-week range
$0.25 – $7.08
Volume
49.32K
Avg. volume
480.27K

Price performance · HCWB

HCWB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

HCWB closed at $1.12 after 21 trading sessions, down 43.72% for the selected period.

Last close
$1.12
Period change
-43.72%
Period low
$1.12
Period high
$1.99
Daily close
View OHLC price history
HCWB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$1.15$1.15$1.10$1.1249.32K
Oct 21, 2026$1.17$1.21$1.15$1.1650.07K
Oct 20, 2026$1.25$1.27$1.17$1.1798.38K
Oct 19, 2026$1.24$1.34$1.23$1.2399.11K
Oct 16, 2026$1.23$1.27$1.22$1.2478.76K
Oct 15, 2026$1.17$1.2795$1.15$1.2348.61K
Oct 14, 2026$1.2408$1.26$1.14$1.1759.86K
Oct 13, 2026$1.30$1.45$1.25$1.262.14M
Oct 12, 2026$1.56$1.60$1.47$1.4842.98K
Oct 9, 2026$1.60$1.7282$1.52$1.6079.98K
Oct 8, 2026$1.59$1.61$1.51$1.5346.38K
Oct 7, 2026$1.55$1.62$1.54$1.5630.68K
Oct 6, 2026$1.61$1.63$1.55$1.5737.83K
Oct 5, 2026$1.64$1.69$1.55$1.6483.29K
Oct 2, 2026$1.66$1.7213$1.65$1.6866.53K
Oct 1, 2026$1.7472$1.7472$1.671$1.6955.7K
Sep 30, 2026$1.77$1.8227$1.71$1.7148.41K
Sep 29, 2026$1.81$1.85$1.75$1.7552.06K
Sep 28, 2026$1.86$1.895$1.71$1.82104.53K
Sep 25, 2026$1.88$2.00$1.81$1.93418.79K
Sep 24, 2026$1.69$3.12$1.67$1.9913.67M

Latest HCWB news

The latest Smart Investors Daily articles mentioning HCWB.

Stock researchCompany · Overview

HCWB research

Overview

Company profile and research snapshot.

Company profile

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
HCWB recent ratings
DateFirmRatingTarget
May 28, 2026Maxim GroupBuy—
May 29, 2025Maxim GroupBuy—
Apr 19, 2023EF HuttonBuy—
Mar 30, 2023EF HuttonBuy—
Mar 23, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologic

Yahoo · Sep 24, 2026

HCW Biologics Announces Pricing of $1.5 Million Private Placement

MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”). Pursuant to a securities purchase agreement entered into on Sept

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By